TY - JOUR
T1 - Skeletal muscle ischemia-reperfusion injury and cyclosporine A in the aging rat
AU - Pottecher, Julien
AU - Kindo, Michel
AU - Chamaraux-Tran, Thiên Nga
AU - Charles, Anne Laure
AU - Lejay, Anne
AU - Kemmel, Véronique
AU - Vogel, Thomas
AU - Chakfe, Nabil
AU - Zoll, Joffrey
AU - Diemunsch, Pierre
AU - Geny, Bernard
N1 - Publisher Copyright:
© 2016 Société Française de Pharmacologie et de Thérapeutique.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Old patients exhibit muscle impairments and increased perioperative risk during vascular surgery procedures. Although aging generally impairs protective mechanisms, data are lacking concerning skeletal muscle in elderly. We tested whether cyclosporine A (CsA), which protects skeletal muscle from ischemia-reperfusion (IR) in young rats, might reduce skeletal muscle mitochondrial dysfunction and oxidative stress in aging rats submitted to hindlimb IR. Wistar rats aged 71-73 weeks were randomized to IR (3 h unilateral tourniquet application and 2 h reperfusion) or IR + CsA (10 mg/kg cyclosporine IV before reperfusion). Maximal oxidative capacity (VMax), acceptor control ratio (ACR), and relative contribution of the mitochondrial respiratory chain complexes II, III, IV (VSucc), and IV (VTMPD/Asc), together with calcium retention capacity (CRC) a marker of apoptosis, and tissue reactive oxygen species (ROS) production were determined in gastrocnemius muscles from both hindlimbs. Compared to the nonischemic hindlimb, IR significantly reduced mitochondrial coupling, VMax (from 7.34 ± 1.50 to 2.87 ± 1.22 μMO2/min/g; P < 0.05; -70%), and VSucc (from 6.14 ± 1.07 to 3.82 ± 0.83 μMO2/min/g; P < 0.05; -42%) but not VTMPD/Asc. IR also decreased the CRC from 15.58 ± 3.85 to 6.19 ± 0.86 μMCa2+/min/g; P < 0.05; -42%). These alterations were not corrected by CsA (-77%, -49%, and -32% after IR for VMax, VSucc, and CRC, respectively). Further, CsA significantly increased ROS production in both hindlimbs (P < 0.05; +73%). In old rats, hindlimb IR impairs skeletal muscle mitochondrial function and increases oxidative stress. Cyclosporine A did not show protective effects.
AB - Old patients exhibit muscle impairments and increased perioperative risk during vascular surgery procedures. Although aging generally impairs protective mechanisms, data are lacking concerning skeletal muscle in elderly. We tested whether cyclosporine A (CsA), which protects skeletal muscle from ischemia-reperfusion (IR) in young rats, might reduce skeletal muscle mitochondrial dysfunction and oxidative stress in aging rats submitted to hindlimb IR. Wistar rats aged 71-73 weeks were randomized to IR (3 h unilateral tourniquet application and 2 h reperfusion) or IR + CsA (10 mg/kg cyclosporine IV before reperfusion). Maximal oxidative capacity (VMax), acceptor control ratio (ACR), and relative contribution of the mitochondrial respiratory chain complexes II, III, IV (VSucc), and IV (VTMPD/Asc), together with calcium retention capacity (CRC) a marker of apoptosis, and tissue reactive oxygen species (ROS) production were determined in gastrocnemius muscles from both hindlimbs. Compared to the nonischemic hindlimb, IR significantly reduced mitochondrial coupling, VMax (from 7.34 ± 1.50 to 2.87 ± 1.22 μMO2/min/g; P < 0.05; -70%), and VSucc (from 6.14 ± 1.07 to 3.82 ± 0.83 μMO2/min/g; P < 0.05; -42%) but not VTMPD/Asc. IR also decreased the CRC from 15.58 ± 3.85 to 6.19 ± 0.86 μMCa2+/min/g; P < 0.05; -42%). These alterations were not corrected by CsA (-77%, -49%, and -32% after IR for VMax, VSucc, and CRC, respectively). Further, CsA significantly increased ROS production in both hindlimbs (P < 0.05; +73%). In old rats, hindlimb IR impairs skeletal muscle mitochondrial function and increases oxidative stress. Cyclosporine A did not show protective effects.
KW - Aging
KW - Cyclosporine
KW - Ischemia-reperfusion injury
KW - Mitochondria
KW - Oxidative stress
KW - Skeletal muscle
UR - http://www.scopus.com/inward/record.url?scp=84959422341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959422341&partnerID=8YFLogxK
U2 - 10.1111/fcp.12180
DO - 10.1111/fcp.12180
M3 - Article
C2 - 26787364
AN - SCOPUS:84959422341
SN - 0767-3981
VL - 30
SP - 216
EP - 225
JO - Fundamental and Clinical Pharmacology
JF - Fundamental and Clinical Pharmacology
IS - 3
ER -